Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

被引：1
|
作者：
Croop, Robert [1 ]
Ailani, Jessica [2 ]
Kudrow, David
Smith, Timothy [3 ]
Lipton, Richard [4 ]
Thiry, Alexandra [1 ]
Jensen, Christopher [1 ]
Kamen, Lisa [1 ]
机构：
[1] Biohaven Pharmaceut, New Haven, CT USA
[2] Medstar Georgetown Neurol, Washington, DC USA
[3] Study Metrix Res, St Petersburg, FL USA
[4] Albert Einstein Coll Med, New York, NY USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202051
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P10-12.010
引用
收藏
页数：6
相关论文
共 50 条
  • [31] AN OPEN-LABEL, 52-WEEK EXTENSION STUDY ASSESSING TOLERABILITY AND EFFICACY OF GABAPENTIN ENACARBIL IN SUBJECTS WITH PRIMARY RESTLESS LEGS SYNDROME
    Ellenbogen, A. L.
    Thein, S.
    Winslow, D. H.
    Becker, P. M.
    Tolson, J.
    Conklin, H.
    Lassauzet, M.
    Chen, D.
    SLEEP, 2010, 33 : A263 - A263
  • [32] Sustained remission and symptom stability in patients with schizophrenia receiving aripiprazole once-monthly: a 52-week, open-label, maintenance study
    Peters-Strickland, T.
    Jin, N.
    Such, P.
    Salzman, P. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S942 - S943
  • [33] Long-term efficacy and safety of aripiprazole vs. olanzapine in schizophrenia:: a 52-week, open-label extension study
    Ebrecht, M
    Modell, S
    Werner, C
    Spevakné-Göröcs, T
    Kungel, M
    PHARMACOPSYCHIATRY, 2005, 38 (05) : 238 - 238
  • [34] Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study
    Koster, Matthew J.
    Crowson, Cynthia S.
    Giblon, Rachel E.
    Jaquith, Jane M.
    Duarte-Garcia, Ali
    Matteson, Eric L.
    Weyand, Cornelia M.
    Warrington, Kenneth J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 861 - 867
  • [35] Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
    Jacobsen, Paula L.
    Harper, Linda
    Chrones, Lambros
    Chan, Serena
    Mahableshwarkar, Atul R.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (05) : 255 - 264
  • [36] Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan
    Matsumoto, Hideo
    Ishigooka, Jun
    Ono, Hiroaki
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (09) : 701 - 712
  • [37] Long-Term, Open-Label Safety Study of Rimegepant 75 mg for the Treatment of Migraine (Study 201): Interim Analysis of Safety and Exploratory Efficacy
    Lipton, R. B.
    Berman, G.
    Kudrow, D.
    Mullin, K.
    Thiry, A. C.
    Lovegren, M.
    Coric, V
    Croop, R.
    HEADACHE, 2019, 59 : 175 - 175
  • [38] Long-Term, Open-Label Safety Study of Rimegepant 75 mg for the Treatment of Migraine (Study 201): Interim Analysis of Safety and Exploratory Efficacy
    Lipton, Richard B.
    Berman, Gary
    Kudrow, David
    Mullin, Kathleen
    Thiry, Alexandra
    Lovegren, Meghan
    Coric, Vladimir
    Croop, Robert
    CEPHALALGIA, 2019, 39 : 189 - 189
  • [39] Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
    Saito, Takuya
    Hyodo, Yohei
    Sakaguchi, Reiko
    Nakamura, Hiroshi
    Ishigooka, Jun
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2022, 32 (01) : 24 - 35
  • [40] An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Wernicke, Joachim F.
    Wang, Fujun
    Pritchett, Yili L.
    Smith, Timothy R.
    Raskin, Joel
    D'Souza, Deborah N.
    Iyengar, Smriti
    Chappell, Amy S.
    PAIN MEDICINE, 2007, 8 (06) : 503 - 513
12345